- Market Capitalization, $K 188,086
- Shares Outstanding, K 88,720
- Annual Sales, $ 1,720 K
- Annual Income, $ -40,490 K
- 60-Month Beta 2.18
- Price/Sales 120.25
- Price/Cash Flow N/A
- Price/Book 4.98
|Period||Period Low||Period High||Performance|
| || |
-0.87 (-29.10%)since 06/30/21
| || |
-1.21 (-36.34%)since 04/30/21
| || |
+1.29 (+155.98%)since 07/30/20
Infinity (INFI) delivered earnings and revenue surprises of 0.00% and 30.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Tuesday reported a loss of $11.3 million in its second quarter.
--- MARIO-3 TNBC early data suggest the addition of eganelisib to standard of care regimens extends progression free survival regardless of PD-L1 status with majority of patients still on treatment -
--- Increases seen in overall survival in 2L urothelial cancer (UC) and in progression free survival in 1L triple negative breast cancer (TNBC), in both cases regardless of PD-L1 status -
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
--- MARIO-275 Phase 2 study evaluating the addition of eganelisib to standard of care Opdivo(R) in metastatic 2L urothelial cancer (UC)-
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which...
Infinity (INFI) delivered earnings and revenue surprises of -7.14% and 0.86%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Thursday reported a loss of $11.6 million in its first quarter.
---Update for eganelisib in PD-L1 low, 2L advanced UC patients expected mid-year-
|Alps Medical Breakthroughs ETF|
|U.S. Momentum Factor Vanguard ETF|
|Micro-Cap Ishares ETF|
|Principal Healthcare Innovators Index|
|GS Activebeta U.S. Small Cap Equity ETF|